HomeNewsIndiaCalls for debt monetisation gain traction as COVID-19 cripples economy

Calls for debt monetisation gain traction as COVID-19 cripples economy

After the government over the weekend hiked market borrowing by 54 per cent in the wake of the coronavirus pandemic, calls for monetising debt seem to be gaining traction

May 10, 2020 / 19:44 IST
Story continues below Advertisement

After the government over the weekend hiked market borrowing by 54 per cent in the wake of the coronavirus pandemic, calls for monetising debt seem to be gaining traction with experts saying that repercussions of not spending to support the economy will be irreparable.

Conservative monetary economist and former RBI chief Raghuram Rajan, over the weekend, has also pitched for monetising public debt and higher fiscal deficit in a ''measured'' manner to protect the economy and the poor and the vulnerable in these ''abnormal times''.

Story continues below Advertisement

The first such call came in early April when Kerala Finance Minister Thomas Isaac after the state had to pay a tad less than 9 per cent for Rs 6,000-crore market borrowing to meet the exigencies arising from the pandemic.

Coronavirus has snuffed out lives of more than 2,100 people and infected nearly 63,000 in India. Globally, the death toll is over 2.79 lakh and more than 40 lakh have been infected.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show